Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Boston, Massachusetts

This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
21516
Shown on this page
12
Current sort
Recently updated
Location scope
Boston, MA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Boston, Massachusetts. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 421–432 of 21,516 matching trials in Boston, MA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Boston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

NCT06668064
View directory record Official record
Conditions
Wet Age Related Macular Degeneration, wAMD
Interventions
EYP-1901, Aflibercept (2.0 mg)
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 70 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:51 AM EST
Active, not recruiting Phase 2 Interventional

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

NCT07546812
View directory record Official record
Conditions
HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Interventions
Denikitug, Nivolumab, Ramucirumab, Paclitaxel
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Boston, Massachusetts • Albany, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:51 AM EST
Completed Phase 2 Interventional Results available

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

NCT04530123
View directory record Official record
Conditions
Celiac Disease
Interventions
Placebo, TAK-101, Gluten
Drug · Dietary Supplement
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Escondido, California • Poway, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:51 AM EST
Completed Phase 2 Interventional Results available

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

NCT04929379
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Fenofibrate, Placebo
Drug · Other
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:51 AM EST
Recruiting No phase listed Observational

Prospective Screening for Breast Cancer-related Lymphedema

NCT01521741
View directory record Official record
Conditions
Lymphedema
Interventions
Breast Cancer-Related Lymphedema Screening
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:51 AM EST
Recruiting Not applicable Interventional

Harness-based Mobility Intervention for Infants With Down Syndrome

NCT06219863
View directory record Official record
Conditions
Down Syndrome
Interventions
Body weight supported harness
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
Up to 2 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:51 AM EST
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

NCT07065240
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions
SPT-300, Placebo
Drug
Lead sponsor
Seaport Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Chino, California • Garden Grove, California • Glendale, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:51 AM EST
Active, not recruiting Phase 3 Interventional Results available

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

NCT02951052
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:51 AM EST
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Optical Imaging of Gastrointestinal Biopsy Samples and Their Correlation With Histology

NCT04565704
View directory record Official record
Conditions
Gastrointestinal Disease, Gastrointestinal Dysfunction
Interventions
Biopsy imaged by Optical imaging device.
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:51 AM EST
Not yet recruiting Phase 3 Interventional

The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease

NCT07907991
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Verducatib, Placebo matching verducatib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Palma, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:51 AM EST
Completed Phase 3 Interventional Results available

Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function

NCT04119843
View directory record Official record
Conditions
Known or Suspected Focal Liver Lesions, Severe Renal Impairment
Interventions
Mangoral
Drug
Lead sponsor
Ascelia Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:51 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Meditation and Yogic Breathing-driven Modulation of Neurofluid Coupling and Brain Clearance

NCT07903688
View directory record Official record
Conditions
Healthy
Interventions
Nadi Shuddhi, Shoonya Meditation
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
25 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:51 AM EST